StockData
BillionToOne, Inc. logo

BillionToOne, Inc. (BLLN) stock

BLLNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30
$97.50+1.19 (+1.24%)

Close on Nov 17, 2026Market cap $4.60BP/E –Yield –

BillionToOne r&d expenses

Research and development expenses are spending on new products and technology.

BillionToOne's R&D Expenses for the twelve months ending Sep 30, 2026 was $66.47M, up 44.1% year over year. For fiscal 2025 it was $49.38M, up 34.9% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$49.38M+34.9%
FY2024Dec 31, 2024$36.60M+63.3%
FY2023Dec 31, 2023$22.41M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$20.22M+56.1%
Q2 FY2026Jun 30, 2026$17.32M+47.3%
Q1 FY2026Mar 31, 2026$14.69M+40.9%
Q4 FY2025Dec 31, 2025$14.25M+29.6%
Q3 FY2025Sep 30, 2025$12.95M+35.6%
Q2 FY2025Jun 30, 2025$11.75M–
Q1 FY2025Mar 31, 2025$10.43M–
Q4 FY2024Dec 31, 2024$11.00M–
Q3 FY2024Sep 30, 2024$9.55M–

More BillionToOne figures

See a number that looks wrong?